U2Bio Co (XKRX:221800) Cash-to-Debt : 81.35 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is U2Bio Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. U2Bio Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 81.35.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, U2Bio Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for U2Bio Co's Cash-to-Debt or its related term are showing as below:

XKRX:221800' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.49 Max: 81.35
Current: 81.35

During the past 9 years, U2Bio Co's highest Cash to Debt Ratio was 81.35. The lowest was 0.02. And the median was 0.49.

XKRX:221800's Cash-to-Debt is ranked better than
91.2% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.295 vs XKRX:221800: 81.35

U2Bio Co Cash-to-Debt Historical Data

The historical data trend for U2Bio Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

U2Bio Co Cash-to-Debt Chart

U2Bio Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.48

0.53

8.29

70.79

81.35

U2Bio Co Semi-Annual Data
	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	N/A	70.79	94.23	81.35

Competitive Comparison of U2Bio Co's Cash-to-Debt

For the Diagnostics & Research subindustry, U2Bio Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U2Bio Co's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, U2Bio Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where U2Bio Co's Cash-to-Debt falls into.

U2Bio Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

U2Bio Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	36791.885	/	(260.307	+	191.958)
	=	81.35

U2Bio Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	36791.885	/	(260.307	+	191.958)
	=	81.35

U2Bio Co (XKRX:221800) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

U2Bio Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of U2Bio Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

U2Bio Co (XKRX:221800) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » U2Bio Co Ltd (XKRX:221800) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Basement 1, 68 Gumaro Songpagu, Seoul, KOR

Website

http://www.u2bio.co.kr

U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.

U2Bio Co (XKRX:221800) Headlines

No Headlines